212 related articles for article (PubMed ID: 29773266)
1. Genetic interferonopathies: An overview.
Eleftheriou D; Brogan PA
Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
[TBL] [Abstract][Full Text] [Related]
2. [Type I interferonopathies].
Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
[TBL] [Abstract][Full Text] [Related]
3. Type I interferonopathies in pediatric rheumatology.
Volpi S; Picco P; Caorsi R; Candotti F; Gattorno M
Pediatr Rheumatol Online J; 2016 Jun; 14(1):35. PubMed ID: 27260006
[TBL] [Abstract][Full Text] [Related]
4. Insights from Mendelian Interferonopathies: Comparison of CANDLE, SAVI with AGS, Monogenic Lupus.
Kim H; Sanchez GA; Goldbach-Mansky R
J Mol Med (Berl); 2016 Oct; 94(10):1111-1127. PubMed ID: 27678529
[TBL] [Abstract][Full Text] [Related]
5. Type I interferonopathies: a novel set of inborn errors of immunity.
Crow YJ
Ann N Y Acad Sci; 2011 Nov; 1238():91-8. PubMed ID: 22129056
[TBL] [Abstract][Full Text] [Related]
6. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
[TBL] [Abstract][Full Text] [Related]
7. Type I interferonopathies: mendelian type I interferon up-regulation.
Crow YJ
Curr Opin Immunol; 2015 Feb; 32():7-12. PubMed ID: 25463593
[TBL] [Abstract][Full Text] [Related]
8. Novel interferonopathies associated with mutations in RIG-I like receptors.
Buers I; Nitschke Y; Rutsch F
Cytokine Growth Factor Rev; 2016 Jun; 29():101-7. PubMed ID: 26993858
[TBL] [Abstract][Full Text] [Related]
9. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
Yu ZX; Song HM
World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
[TBL] [Abstract][Full Text] [Related]
10. Aicardi-Goutières syndrome and the type I interferonopathies.
Crow YJ; Manel N
Nat Rev Immunol; 2015 Jul; 15(7):429-40. PubMed ID: 26052098
[TBL] [Abstract][Full Text] [Related]
11. [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].
Günther C; Schmidt F; König N; Lee-Kirsch MA
Z Rheumatol; 2016 Mar; 75(2):134-40. PubMed ID: 26744186
[TBL] [Abstract][Full Text] [Related]
12. Type I Interferonopathies: A Clinical Review.
Wang CS
Rheum Dis Clin North Am; 2023 Nov; 49(4):741-756. PubMed ID: 37821193
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
[TBL] [Abstract][Full Text] [Related]
14. [Type I interferonopathies. Literature review].
Picard C; Belot A
Rev Med Interne; 2018 Apr; 39(4):271-278. PubMed ID: 27659742
[TBL] [Abstract][Full Text] [Related]
15. Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies.
Pescarmona R; Belot A; Villard M; Besson L; Lopez J; Mosnier I; Mathieu AL; Lombard C; Garnier L; Frachette C; Walzer T; Viel S
Cytokine; 2019 Jan; 113():446-452. PubMed ID: 30413290
[TBL] [Abstract][Full Text] [Related]
16. Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies.
Lodi L; Melki I; Bondet V; Seabra L; Rice GI; Carter E; Lepelley A; Martin-Niclós MJ; Al Adba B; Bader-Meunier B; Barth M; Blauwblomme T; Bodemer C; Boespflug-Tanguy O; Dale RC; Desguerre I; Ducrocq C; Dulieu F; Dumaine C; Ellul P; Hadchouel A; Hentgen V; Hié M; Hully M; Jeziorski E; Lévy R; Mochel F; Orcesi S; Passemard S; Pouletty M; Quartier P; Renaldo F; Seidl R; Shetty J; Neven B; Blanche S; Duffy D; Crow YJ; Frémond ML
J Clin Immunol; 2021 Apr; 41(3):603-609. PubMed ID: 33411153
[TBL] [Abstract][Full Text] [Related]
17. The Type I Interferonopathies.
Lee-Kirsch MA
Annu Rev Med; 2017 Jan; 68():297-315. PubMed ID: 27813875
[TBL] [Abstract][Full Text] [Related]
18. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
de Jesus AA; Hou Y; Brooks S; Malle L; Biancotto A; Huang Y; Calvo KR; Marrero B; Moir S; Oler AJ; Deng Z; Montealegre Sanchez GA; Ahmed A; Allenspach E; Arabshahi B; Behrens E; Benseler S; Bezrodnik L; Bout-Tabaku S; Brescia AC; Brown D; Burnham JM; Caldirola MS; Carrasco R; Chan AY; Cimaz R; Dancey P; Dare J; DeGuzman M; Dimitriades V; Ferguson I; Ferguson P; Finn L; Gattorno M; Grom AA; Hanson EP; Hashkes PJ; Hedrich CM; Herzog R; Horneff G; Jerath R; Kessler E; Kim H; Kingsbury DJ; Laxer RM; Lee PY; Lee-Kirsch MA; Lewandowski L; Li S; Lilleby V; Mammadova V; Moorthy LN; Nasrullayeva G; O'Neil KM; Onel K; Ozen S; Pan N; Pillet P; Piotto DG; Punaro MG; Reiff A; Reinhardt A; Rider LG; Rivas-Chacon R; Ronis T; Rösen-Wolff A; Roth J; Ruth NM; Rygg M; Schmeling H; Schulert G; Scott C; Seminario G; Shulman A; Sivaraman V; Son MB; Stepanovskiy Y; Stringer E; Taber S; Terreri MT; Tifft C; Torgerson T; Tosi L; Van Royen-Kerkhof A; Wampler Muskardin T; Canna SW; Goldbach-Mansky R
J Clin Invest; 2020 Apr; 130(4):1669-1682. PubMed ID: 31874111
[TBL] [Abstract][Full Text] [Related]
19. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview.
Rodero MP; Crow YJ
J Exp Med; 2016 Nov; 213(12):2527-2538. PubMed ID: 27821552
[TBL] [Abstract][Full Text] [Related]
20. Systemic Autoimmunity in a Patient With CANDLE Syndrome.
Yamazaki-Nakashimada MA; Santos-Chávez EE; de Jesus AA; Rivas-Larrauri F; Guzmán-Martínez MN; Goldbach-Mansky R; Espinosa-Padilla S; Sáez-de-Ocariz MD; Orozco-Covarrubias L; Blancas-Galicia L
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):75-76. PubMed ID: 30785112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
